Our HTGF Portfolio of startups offers excellent opportunities and is always hiring talented people.
Personalised therapies for the heart and vasculature. Innovative, independent, close to the patient. We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies. We work closely together with excellent academic and clinical teams in basic and clinical research. We use state-of-the-art analytical methods, and we develop our products according to the highest quality standards (GLP, GMP, and GCP). Revacept is a therapeutic agent for the prevention and treatment of acute arterial thrombosis, which can lead to heart attack, acute limb ischemia, and stroke. A Phase II clinical trial in 160 patients with stroke or transient ischaemic attack (TIA) has been completed. It showed beneficial effects in patients treated with 120 milligrams (mg) of Revacept.
Something looks off?